Aminoglycosides

01/01/1985 - "High therapeutic efficacy of the above three aminoglycosides in the treatment of severe inflammatory infections caused by gram-negative bacteria was shown with the use of the adequate doses. "
12/01/1979 - "These survival data were supported by studies showing superior clearance of viable Pseudomonas from lung tissues in aminoglycoside-treated animals chosen at random for sacrifice 3 hr after infection. "
12/01/1991 - "The improved survival was achieved by attaining therapeutic peak serum concentrations earlier in the course of the infection and by administering more total aminoglycoside without increasing toxicity. "
08/15/1994 - "An increasing number of clinical trials suggest tht once-daily administration of aminoglycosides and regimens involving shorter dosage intervals are equally effective in patients with normal renal function and gram-negative infections and that once-daily administration may reduce the frequency of toxicity or delay it. "
02/01/2005 - "Once-daily aminoglycoside dosing is effective in treating gram-negative infections, including those associated with bones and joints."

07/01/2012 - "Aminoglycosides are highly effective against bacteria but have serious side-effects including ototoxicity and nephrotoxicity. "
01/01/2003 - "Clinically, increased levels of SOD or SOD mimetics might provide significant protection against aminoglycoside ototoxicity."
06/22/1990 - "Several experimental studies support a once-daily dosing regimen for aminoglycosides (comparable or better efficacy with less ototoxicity and nephrotoxicity). "
02/10/1996 - "Once daily administration of aminoglycosides in patients without pre-existing renal impairment is as effective as multiple daily dosing, has a lower risk of nephrotoxicity, and no greater risk of ototoxicity. "
06/01/2022 - "Here, we studied the protective effects and underlying mechanism of NRH on aminoglycoside-induced ototoxicity. "

01/01/2021 - "The use of aminoglycosides for the treatment of endocarditis has been dramatically reduced over the last 20 years. "
08/01/2016 - "Aminoglycosides are a mainstay of treatment for enterococcal infective endocarditis. "
03/01/2020 - "Studies investigating multiple daily dosing aminoglycoside regimens, infective endocarditis and febrile neutropaenia were excluded. "
08/01/2016 - "The aim of this study was to determine if adjunctive aminoglycoside treatment after surgery for enterococcal endocarditis leads to better outcomes. "
02/01/2009 - "The evidence from randomized trials in humans does not support the use of aminoglycosides in staphylococcal or streptococcal endocarditis, and is lacking for endocarditis caused by enterococci. "

01/01/2000 - "This systematic review has highlighted the need for a well designed, adequately-powered, multicentre, randomised controlled trial assessing the efficacy of once-daily versus multiple-daily dosing of intravenous aminoglycosides for pulmonary exacerbations in cystic fibrosis."
01/01/2019 - "All randomised controlled trials, whether published or unpublished, in which once-daily dosing of aminoglycosides has been compared with multiple-daily dosing in terms of efficacy or toxicity or both, in people with cystic fibrosis. "
01/01/2017 - "All randomised controlled trials, whether published or unpublished, in which once-daily dosing of aminoglycosides has been compared with multiple-daily dosing in terms of efficacy or toxicity or both, in people with cystic fibrosis. "
02/04/2014 - "All randomised controlled trials, whether published or unpublished, in which once-daily dosing of aminoglycosides has been compared with multiple-daily dosing in terms of efficacy or toxicity or both, in people with cystic fibrosis. "
02/15/2012 - "All randomised controlled trials, whether published or unpublished, in which once-daily dosing of aminoglycosides has been compared with multiple-daily dosing in terms of efficacy or toxicity or both, in people with cystic fibrosis. "

08/01/2007 - "That approach may help to prevent aminoglycoside-induced hearing loss in these high-risk patients in daily practice."
11/28/1999 - "Both hearing loss and vestibular dysfunction induced by several aminoglycosides were significantly attenuated without compromising the antibacterial efficacy of the drugs. "
07/15/1998 - "The present study investigated whether this protective treatment is effective against hearing loss and vestibular damage caused by other aminoglycosides. "
06/14/2022 - "In conclusion, the AAV-CasRx-gRNA-mediated knockdown of Htra2 transcript in mice has been proved effective and safe for preventing hearing loss induced by aminoglycosides and, thus, represents a promising genetic approach for the future clinical applications for treating non-inherited hearing loss."
01/01/2017 - "Once verified, these mechanisms will be potential targets for novel pharmacotherapeutics that reduce the risk of drug-induced hearing loss (and acute kidney damage) without compromising the life-saving bactericidal efficacy of aminoglycosides."